Compounds > 2-hydroxy-4-methoxy benzoic acid
Page last updated: 2024-11-06

2-hydroxy-4-methoxy benzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-hydroxy-4-methoxy benzoic acid, also known as vanillic acid, is a naturally occurring phenolic compound found in various plants. It is a derivative of benzoic acid with a hydroxyl group at the 2-position and a methoxy group at the 4-position. It is often synthesized through the oxidation of vanillin, a common flavoring agent. Vanillic acid has shown antioxidant, anti-inflammatory, and anti-cancer properties in research studies. It is also involved in plant defense mechanisms against pathogens. The compound's potential as a therapeutic agent has led to its extensive study, especially in relation to its effects on various biological systems. '

Cross-References

ID SourceID
PubMed CID75231
CHEMBL ID507095
CHEBI ID167809
SCHEMBL ID483346
MeSH IDM0290990

Synonyms (44)

Synonym
smr000127395
4-methoxysalicylic acid
MLS000517276
CHEBI:167809
NCIOPEN2_001552
nsc-94304
nsc94304
2237-36-7
2-hydroxy-4-methoxybenzoic acid, 99%
2-hydroxy-4-methoxybenzoic acid
STK065285
AC-11620
M1795
2-hydroxy-p-anisic acid
CHEMBL507095
AKOS000120626
NCGC00246993-01
HMS2269N04
einecs 218-801-0
nsc 94304
FT-0618866
PS-3720
S5160
MRIXVKKOHPQOFK-UHFFFAOYSA-N
4-methoxy-salicylic acid
2-hydroxy-4-methoxy-benzoic acid
4-methoxy salicylic acid
SY008083
mfcd00002450
SCHEMBL483346
W-107479
STR06769
AC-34348
benzoic acid, 2-hydroxy-4-methoxy-
DTXSID50176906
4-methoxy-2-hydroxobenzoic acid
HY-75625
CS-0006868
AMY18271
CCG-266345
2-hydroxy-4-methoxybenzoicacid
EN300-21485
PD088240
Z104499836
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methoxybenzoic acidAny benzoic acid carrying one or more methoxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
gemininHomo sapiens (human)Potency32.64270.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1291733Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 6 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1163259Cytotoxicity against mouse RAW264.7 cells assessed as survival rate at 10 uM after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
AID1291742Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 6 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to 2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID338333Antiplatelet activity against rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.5 mg/ml pretreated 2 mins before arachidonic acid challenge
AID1163261Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level at 10 uM incubated for 4 days by TRAP staining assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
AID1090826Antifeedant activity against Hylobius abietis (pine weevil ) in compound pre-treated Scots pine twig at 50 mM measured after 24 hr by two-choice laboratory bioassay2007Journal of agricultural and food chemistry, Nov-14, Volume: 55, Issue:23
Quantitative structure-activity relationships of pine weevil antifeedants, a multivariate approach.
AID1291750Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 6 mmol, iv administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291734Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 6 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291745Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 6 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID338336Antiplatelet activity against rat platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 0.25 mg/ml pretreated 2 mins before collagen challenge
AID1291741Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 6 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mous2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291737Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 6 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291738Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 6 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291746Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 6 mmol, iv administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291749Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 6 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291753Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 6 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID657641Immunosuppressive activity in BALB/c mouse lymph node cells assessed as inhibition of concanavalin A-stimulated cell proliferation at 1 uM administered 24 hrs post concanavalin A stimulation and measured 72 hrs after compound dosing by MTT assay2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
AID1163260Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
AID1291752Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 6 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-hydroxybenzaldehyde
[no description available]		2.1310hydroxybenzaldehyde
4-hydroxybenzaldehyde
[no description available]		2.1310hydroxybenzaldehydeEC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor;
mouse metabolite;
plant metabolite
4-hydroxybenzoic acid
4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.		2.0310monohydroxybenzoic acidalgal metabolite;
plant metabolite
benzaldehyde
[no description available]		2.1310benzaldehydesEC 3.1.1.3 (triacylglycerol lipase) inhibitor;
EC 3.5.5.1 (nitrilase) inhibitor;
flavouring agent;
fragrance;
odorant receptor agonist;
plant metabolite
catechol
[no description available]		2.1310catecholsallelochemical;
genotoxin;
plant metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		2.4620monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
hydroquinone
[no description available]		2.1310benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
phenol
[no description available]		2.1310phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
vanillin
Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).		2.1310benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.1310benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.0710chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
resorcinol
resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951. resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3.		2.1310benzenediol;
phenolic donor;
resorcinols		erythropoietin inhibitor;
sensitiser
salicylaldehyde
o-hydroxybenzaldehyde: structure in first source		2.1310hydroxybenzaldehydenematicide;
plant metabolite
veratrole
veratrole: structure. dimethoxybenzene : Any methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.. veratrole : A dimethoxybenzene with the methoxy groups at ortho-positions.		2.1310dimethoxybenzeneplant metabolite
veratric acid
veratric acid: RN given refers to parent cpd; structure. 3,4-dimethoxybenzoic acid : A member of the class of benzoic acids that is benzoic acid substituted by methoxy groups at positions 2 and 3.		2.0310benzoic acidsallergen;
plant metabolite
piperonylic acid
piperonylic acid: RN given refers to parent cpd; structure. piperonylic acid : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a carboxy group at position 5. It is a natural product isolated from several plant species. It is a selective mechanism-based inactivator of the trans-cinnamate 4-hydroxylase enzyme and exhibits antifungal and skin wound healing properties.		2.0310aromatic carboxylic acid;
benzodioxoles;
monocarboxylic acid		antifungal agent;
EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor;
plant metabolite;
vulnerary
2,4-dihydroxybenzaldehyde
2,4-dihydroxybenzaldehyde : A dihydroxybenzaldehyde that is resorcinol which has been substituted by a formyl group para to one of the hydroxy groups.		2.1310dihydroxybenzaldehyde
alpha-resorcylic acid
alpha-resorcylic acid: RN given refers to parent cpd. 3,5-dihydroxybenzoic acid : A dihydroxybenzoic acid in which the hydroxy groups are located at positions 3 and 5.		2.0310dihydroxybenzoic acid;
resorcinols		metabolite
methyl gallate
methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.		2.0310gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
methylparaben
methylparaben: used as a preservative in cosmetics but potentiates UV-induced damage of skin; RN given refers to parent cpd. methylparaben : A 4-hydroxybenzoate ester resulting from the formal condensation of the carboxy group of 4-hydroxybenzoic acid with methanol. It is the most frequently used antimicrobial preservative in cosmetics. It occurs naturally in several fruits, particularly in blueberries.		2.0310parabenantifungal agent;
antimicrobial food preservative;
neuroprotective agent;
plant metabolite
anisole
anisole : A monomethoxybenzene that is benzene substituted by a methoxy group.		2.1310monomethoxybenzeneplant metabolite
ethyl vanillin
ethyl vanillin : A member of the class of benzaldehydes that is vanillin in which the methoxy group is replaced by an ethoxy group.		2.1310aromatic ether;
benzaldehydes;
phenols		antioxidant;
flavouring agent
vanillic acid
Vanillic Acid: A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).. vanillic acid : A monohydroxybenzoic acid that is 4-hydroxybenzoic acid substituted by a methoxy group at position 3.		2.0310methoxybenzoic acid;
monohydroxybenzoic acid		plant metabolite
methyl 4-anisate
methyl 4-anisate: volatile biomarker of Mycobacterium tuberculosis; structure in first source. methyl p-anisate : A benzoate ester obtained by the formal condensation of the carboxy group of 4-methoxybenzoic acid with methanol.		2.0310benzoate ester;
monomethoxybenzene
2-Methoxybenzaldehyde
[no description available]		2.1310carbonyl compound
protocatechualdehyde
protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure		2.1310dihydroxybenzaldehyde
2-vanillin
ortho-vanillin : A member of the class of benzaldehydes that is salicylaldehyde substituted by a methoxy group at position 3.		2.1310benzaldehydes;
guaiacols		antimutagen;
plant metabolite
1,4-dimethoxybenzene
1,4-dimethoxybenzene: structure given in first source		2.1310dimethoxybenzene
1,3-dimethoxybenzene
1,3-dimethoxybenzene: structure given in first source		2.1310methoxybenzenes
syringic acid
syringic acid: RN given refers to parent cpd; structure in third source. syringic acid : A dimethoxybenzene that is 3,5-dimethyl ether derivative of gallic acid.		2.0310benzoic acids;
dimethoxybenzene;
phenols		plant metabolite
3-methoxybenzaldehyde
3-methoxybenzaldehyde : A member of the class of benzaldehydes in which the hydrogen at position 3 of benzaldehyde has been replaced by a methoxy group.		2.1310benzaldehydes;
monomethoxybenzene		Brassica napus metabolite
isovanillin
isovanillin: inhibits aldehyde oxidase. isovanillin : A member of the class of benzaldehydes that is 4-methoxybenzaldehyde substituted by a hydroxy group at position 3. It is an inhibitor of aldehyde oxidase.		2.1310benzaldehydes;
monomethoxybenzene;
phenols		animal metabolite;
antidiarrhoeal drug;
antifungal agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
HIV protease inhibitor;
plant metabolite
isovanillic acid
3-hydroxy-4-methoxybenzoic acid : A methoxybenzoic acid that is 4-methoxybenzoic acid bearing a hydroxy substituent at position 3.		2.0310methoxybenzoic acid;
monohydroxybenzoic acid		antibacterial agent;
plant metabolite
3,4,5-trimethoxybenzamide
[no description available]		2.0310
methyl vanillate
methyl vanillate: isolated from Hovenia dulcis. methyl vanillate : A benzoate ester that is the methyl ester of vanillic acid.		2.0310aromatic ether;
benzoate ester;
phenols		antioxidant;
plant metabolite
4-anisaldehyde
4-anisaldehyde: RN given refers to cpd with specified locants for methoxy moieties; structure in Merck, 9th ed, #696. p-methoxybenzaldehyde : A member of the class of benzaldehydes consisting of benzaldehyde itself carrying a methoxy substituent at position 4.		2.1310benzaldehydesbacterial metabolite;
human urinary metabolite;
insect repellent;
plant metabolite
2,4-dimethoxybenzaldehyde
[no description available]		2.1310
2-hydroxy-4-methoxybenzaldehyde
2-hydroxy-4-methoxybenzaldehyde: from African medicinal plants: Mondia whitei (Apocynaceae), Rhus vulagaris (Anacardiaceae), Sclerocarya caffra (Anacardiaceae)		2.1310methoxybenzenes;
phenols
3-methoxysalicylic acid
2-hydroxy-3-methoxybenzoic acid: structure in first source		2.0310methoxysalicylic acidmetabolite
methyl syringate
methyl syringate : A benzoate ester obtained by the formal condensation of carboxy group of syringic acid with methanol.		2.0310benzoate ester;
dimethoxybenzene;
phenols		plant metabolite
2,5-dihydroxybenzaldehyde
2,5-dihydroxybenzaldehyde: structure in first source. 2,5-dihydroxybenzaldehyde : A dihydroxybenzaldehyde carrying hydroxy groups at positions 2 and 5.		2.1310dihydroxybenzaldehydehuman metabolite;
mouse metabolite;
Penicillium metabolite
5-methoxysalicylic acid
5-methoxysalicylic acid: enhances intestinal absorption of insulin in rats; RN given refers to parent cpd. 5-methoxysalicylic acid : A methoxysalicylic acid that is salicylic acid which is carrying a methoxy group at position 5.		2.0310methoxysalicylic acidbacterial metabolite;
human urinary metabolite
methyl 2,4-dihydroxy-3,6-dimethyl benzoate
atraric acid: structure in first source; from the stem barks of Newbouldia laevis		2.03104-hydroxybenzoate ester
methyl 3-(4-hydroxyphenyl)propionate
methyl 3-(4-hydroxyphenyl)propionate: a root-exuded compound responsible for biological nitrification inhibition by sorghum (Sorghum bicolor); structure in first source. methyl 3-(4-hydroxyphenyl)propionate : A methyl ester resulting from the formal condensation of the carboxy group of phloretic acid with methanol. It is a nitrification inhibitor and a plant growth regulator.		2.0310methyl ester;
phenols		nitrification inhibitor;
plant growth regulator
2,3-dihydroxybenzaldehyde
dihydroxybenzaldehyde : Any member of the class of benzaldehydes in which the phenyl ring is substituted by two hydroxy groups.		2.1310dihydroxybenzaldehyde
2-hydroxy-5-methoxybenzaldehyde
2-hydroxy-5-methoxybenzaldehyde: structure in first source. 5-methoxysalicylaldehyde : A member of the class of benzaldehydes carrying hydroxy and methoxy substituents at positions 2 and 5 respectively.		2.1310benzaldehydes;
monomethoxybenzene;
phenols
methyl 3,4-dihydroxybenzoate
[no description available]		2.0310catechols;
methyl ester		antioxidant;
neuroprotective agent;
plant metabolite
ethyl cinnamate
ethyl cinnamate: a pine weevil antifeedant; structure in first source		2.0310alkyl cinnamate;
ethyl ester
phenylalanine methyl ester
phenylalanine methyl ester: RN given refers to (L)-isomer. methyl L-phenylalaninate : An alpha-amino acid ester that is the methyl ester of L-phenylalanine.		2.0310alpha-amino acid ester;
L-phenylalanine derivative
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.0710homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
n-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide
N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide: structure in first source		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Bone Loss, Osteoclastic
[description not available]		02.110